MP35-20 ANDROGEN REPLACEMENT THERAPY FOR CANCER-RELATED SYMPTOMS IN MALE ADVANCED CANCER PATIENTS

Abstract

You have accessJournal of UrologyCME1 May 2022MP35-20 ANDROGEN REPLACEMENT THERAPY FOR CANCER-RELATED SYMPTOMS IN MALE ADVANCED CANCER PATIENTS Kouji Izumi, and Atshushi Mizokami Kouji IzumiKouji Izumi More articles by this author , and Atshushi MizokamiAtshushi Mizokami More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002589.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cachexia associated with advanced cancer displays a variety of physical and psychological symptoms. Hypogonadism associated with cancer is reported to cause cachexia and these symptoms. The purpose of this study was to evaluate whether androgen replacement therapy can improve cancer-related symptoms in male advanced cancer patients. METHODS: An investigator-initiated, prospective, randomized controlled study was conducted in male advanced cancer patients. Patients with low serum testosterone levels were randomly assigned to the control group or the testosterone enanthate administration group (testosterone group). Differences in quality of life questionnaires and cachexia-related serum protein levels between groups were assessed to clarify whether testosterone enanthate can improve cachexia. RESULTS: In this study, 41 and 40 patients were randomized in the control and testosterone groups, respectively. Although no significant differences in the change of subscales and total scores in Functional Assessment of Anorexia/Cachexia Treatment were noted from the baseline between the two groups, the testosterone group showed a significantly better change in the “unhappiness” item of the Edmonton Symptom Assessment System at week 12 compared to baseline versus the control group (−1.4 and 0.0 points, respectively; mean, p=0.007). The testosterone group significantly inhibited the change in serum tumor necrotic factor-α level at week 12 from the baseline compared with the control group (+0.4 and +0.1 pg/mL, respectively; mean, p=0.005). CONCLUSIONS: Testosterone enanthate did not improve most of the items in health-related quality of life questionnaires but significantly induced a better change in the “unhappiness” item of the health-related quality of life at week 12 compared with the control, associated with the inhibition of the deterioration of serum TNF-α levels in male advanced cancer patients. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e595 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kouji Izumi More articles by this author Atshushi Mizokami More articles by this author Expand All Advertisement PDF DownloadLoading ...